Next Article in Journal
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications
Previous Article in Journal
Identifying Subgroup at High Risk of Transarterial Chemoembolization Failure Among Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Livers
Volume 5
Issue 1
10.3390/livers5010010
livers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Livers 2023, 3(4), 562-568.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568

by
Azuma Watanabe
1,*,
Ryoko Horigome
1,
Yumiko Nakatsuka
1 and
Shuji Terai
2
1
Department of Gastroenterology, Kameda Daiichi Hospital, 2-5-22 Nishimachi, Konan-ku, Niigata City 9500165, Niigata, Japan
2
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-754 Asahimachidori, Niigata City 9518520, Niigata, Japan
*
Author to whom correspondence should be addressed.
Livers 2025, 5(1), 10; https://doi.org/10.3390/livers5010010
Submission received: 27 January 2025 / Accepted: 30 January 2025 / Published: 27 February 2025
Versions Notes

Error in Table 4

In the original publication [1], there was a mistake in Table 4 (entitled “Changes in clinical parameters before and after pemafibrate therapy”) as published. The BMI “After” value was incorrect. The corrected Table 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. [Google Scholar] [CrossRef]
Table 4. Changes in clinical parameters before and after pemafibrate therapy.
Table 4. Changes in clinical parameters before and after pemafibrate therapy.
VariablesBeforeAfterp Value
Weight (kg)68.3 ± 14.268.9 ± 14.1<0.05
BMI (kg/m2)25.4 ± 4.225.7 ± 4.1<0.05
AST (IU/L)36.1 ± 32.127.8 ± 17.00.005
ALT (IU/L)43.7 ± 43.824.0 ± 13.8<0.001
γ-GPT (IU/L)93.8 ± 210.244.3 ± 129.3<0.001
Platelet (104/μL)24.6 ± 7.226.9 ± 8.6<0.001
M2BPGi0.9 ± 0.70.7 ± 0.5<0.05
Triglyceride (mg/dL)234.6 ± 126.3126.7 ± 68.4<0.001
HDL-C (mg/dL)52.6 ± 12.955.7 ± 11.60.001
LDL-C (mg/dL)118.4 ± 35.2111.9 ± 28.00.06
Cre (mg/dL)0.8 ± 0.20.8 ± 0.20.57
eGFR (mL/min/1.73 m2)73.0 ± 15.273.1 ± 15.50.70
Glucose (mg/dL)138.7 ± 42.1130.4 ± 38.10.15
HbA1c (%)6.5 ± 1.06.4 ± 1.00.87
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers 2025, 5, 10. https://doi.org/10.3390/livers5010010

AMA Style

Watanabe A, Horigome R, Nakatsuka Y, Terai S. Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers. 2025; 5(1):10. https://doi.org/10.3390/livers5010010

Chicago/Turabian Style

Watanabe, Azuma, Ryoko Horigome, Yumiko Nakatsuka, and Shuji Terai. 2025. "Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568" Livers 5, no. 1: 10. https://doi.org/10.3390/livers5010010

APA Style

Watanabe, A., Horigome, R., Nakatsuka, Y., & Terai, S. (2025). Correction: Watanabe et al. Pemafibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. Livers 2023, 3, 562–568. Livers, 5(1), 10. https://doi.org/10.3390/livers5010010

Article Metrics

Back to TopTop